188 related articles for article (PubMed ID: 28029662)
1. Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing.
Feng F; Cheng Q; Yang L; Zhang D; Ji S; Zhang Q; Lin Y; Li F; Xiong L; Liu C; Jiang X
Oncotarget; 2017 Jan; 8(3):5349-5360. PubMed ID: 28029662
[TBL] [Abstract][Full Text] [Related]
2. Establishment and characterization of patient-derived primary cell lines as preclinical models for gallbladder carcinoma.
Feng F; Huang C; Xiao M; Wang H; Gao Q; Chen Z; Xu X; Zhou J; Li F; Li Y; Zhang D; Chang Y; Jiang X
Transl Cancer Res; 2020 Mar; 9(3):1698-1710. PubMed ID: 35117518
[TBL] [Abstract][Full Text] [Related]
3. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
[TBL] [Abstract][Full Text] [Related]
4. Genomic
Li M; Liu F; Zhang F; Zhou W; Jiang X; Yang Y; Qu K; Wang Y; Ma Q; Wang T; Bai L; Wang Z; Song X; Zhu Y; Yuan R; Gao Y; Liu Y; Jin Y; Li H; Xiang S; Ye Y; Zhang Y; Jiang L; Hu Y; Hao Y; Lu W; Chen S; Gu J; Zhou J; Gong W; Zhang Y; Wang X; Liu X; Liu C; Liu H; Liu Y; Liu Y
Gut; 2019 Jun; 68(6):1024-1033. PubMed ID: 29954840
[TBL] [Abstract][Full Text] [Related]
5. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in
Ippen FM; Alvarez-Breckenridge CA; Kuter BM; Fink AL; Bihun IV; Lastrapes M; Penson T; Schmidt SP; Wojtkiewicz GR; Ning J; Subramanian M; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Clin Cancer Res; 2019 Jun; 25(11):3374-3383. PubMed ID: 30796030
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
Pignochino Y; Sarotto I; Peraldo-Neia C; Penachioni JY; Cavalloni G; Migliardi G; Casorzo L; Chiorino G; Risio M; Bardelli A; Aglietta M; Leone F
BMC Cancer; 2010 Nov; 10():631. PubMed ID: 21087480
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling.
Zhang P; Guo Z; Wu Y; Hu R; Du J; He X; Jiao X; Zhu X
PLoS One; 2015; 10(8):e0136193. PubMed ID: 26287365
[TBL] [Abstract][Full Text] [Related]
8. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
9. ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer.
Iyer P; Shrikhande SV; Ranjan M; Joshi A; Gardi N; Prasad R; Dharavath B; Thorat R; Salunkhe S; Sahoo B; Chandrani P; Kore H; Mohanty B; Chaudhari V; Choughule A; Kawle D; Chaudhari P; Ingle A; Banavali S; Gera P; Ramadwar MR; Prabhash K; Barreto SG; Dutt S; Dutt A
Int J Cancer; 2019 Apr; 144(8):2008-2019. PubMed ID: 30304546
[TBL] [Abstract][Full Text] [Related]
10. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived organoids for personalized gallbladder cancer modelling and drug screening.
Yuan B; Zhao X; Wang X; Liu E; Liu C; Zong Y; Jiang Y; Hou M; Chen Y; Chen L; Zhang Y; Wang H; Fu J
Clin Transl Med; 2022 Jan; 12(1):e678. PubMed ID: 35075805
[TBL] [Abstract][Full Text] [Related]
12. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
13. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.
Liu F; Li Y; Ying D; Qiu S; He Y; Li M; Liu Y; Zhang Y; Zhu Q; Hu Y; Liu L; Li G; Pan W; Jin W; Mu J; Cao Y; Liu Y
Signal Transduct Target Ther; 2021 Feb; 6(1):55. PubMed ID: 33563892
[TBL] [Abstract][Full Text] [Related]
14. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
Fang DD; Zhang CC; Gu Y; Jani JP; Cao J; Tsaparikos K; Yuan J; Thiel M; Jackson-Fisher A; Zong Q; Lappin PB; Hayashi T; Schwab RB; Wong A; John-Baptiste A; Bagrodia S; Los G; Bender S; Christensen J; Vanarsdale T
PLoS One; 2013; 8(6):e67258. PubMed ID: 23826249
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of 38 novel patient-derived primary cancer cell lines using multi-region sampling revealing intra-tumor heterogeneity of gallbladder carcinoma.
Feng F; Cheng Q; Li B; Liu C; Wang H; Li B; Xu X; Yu Y; Chen Z; Wu X; Dong H; Chu K; Xie Z; Gao Q; Xiong L; Li F; Yi B; Zhang D; Jiang X
Hum Cell; 2021 May; 34(3):918-931. PubMed ID: 33813726
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity in clonal evolution with genetic progression and divergence in spindle cell carcinoma of the gallbladder.
Arakawa A; Fujii H; Matsumoto T; Hirai S; Suda K
Hum Pathol; 2004 Apr; 35(4):418-23. PubMed ID: 15116321
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
19. Tumor Mutational Burden and Genomic Alterations in Chinese Small Cell Lung Cancer Measured by Whole-Exome Sequencing.
Su S; Zou JJ; Zeng YY; Cen WC; Zhou W; Liu Y; Su DH; Zhang XL; Huang HY; Lei A; Huang ZH; Jin Y; Li L; Su N; Xie YL; Zhao ZG; Liu JX
Biomed Res Int; 2019; 2019():6096350. PubMed ID: 31781628
[TBL] [Abstract][Full Text] [Related]
20. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Zammataro L; Lopez S; Bellone S; Pettinella F; Bonazzoli E; Perrone E; Zhao S; Menderes G; Altwerger G; Han C; Zeybek B; Bianchi A; Manzano A; Manara P; Cocco E; Buza N; Hui P; Wong S; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Angioli R; Raspagliesi F; Scambia G; Choi J; Dong W; Bilguvar K; Alexandrov LB; Silasi DA; Huang GS; Ratner E; Azodi M; Schwartz PE; Pirazzoli V; Stiegler AL; Boggon TJ; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22730-22736. PubMed ID: 31624127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
